https://www.selleckchem.com/products/Nolvadex.html
00387 QALY at a cost of €25,010, yielding an incremental cost effectiveness ratio (ICER) of €6,467,032 / QALY. The model was sensitive to changes made to model inputs. There was no potential of PR being cost-effective. With the Coapt data, the model generated 1.19 QALY gain at a cost of €26,130 yielding an ICER of €21,918 / QALY and at a threshold of €50,000/QALY PR had a probability of 1 of being cost-effective. Cost effectiveness results were conflicting; reconciling differences between trials is a priority and could promote opti
Curtir
Comentario
Compartilhar
